Enovis Corporation reported third-quarter 2025 net sales of $549 million, representing a 9.0% increase on a reported basis and 7.0% growth organically compared to the same period in 2024. Reconstructive sales grew 12.0% on a reported basis and 9.0% organically, while Prevention & Recovery sales increased 6.0% on a reported basis and 4.0% organically. The company reported a third-quarter net loss of $571 million, primarily due to a $548 million non-cash goodwill impairment charge, resulting in a net loss of $9.99 per share. Adjusted EBITDA for the quarter was $95 million, or 17.3% of sales, and adjusted net earnings per diluted share were $0.75. For full-year 2025, Enovis updated its financial outlook, expecting revenue in the range of $2.24 to $2.27 billion, reflecting a $15 million reduction following the divestiture of its Diabetic Footcare business unit in October 2025. Adjusted EBITDA is forecasted at $395-405 million, and adjusted earnings per share guidance was raised to $3.10-3.25. The divestiture is expected to generate up to $60 million in proceeds.